It's not that Zomedica is necessarily a bad pick. The chances of long-term success, though, are higher with another stock.
News & Analysis: Trupanion
The pet medical insurance provider turned in a mixed Q4 performance, but its long-term prospects look solid.
TRUP earnings call for the period ending December 31, 2020.
Here are my three reasons for scooping up more shares of the pet medical insurance stock.
You might not hear much about them, but that could be a good thing.
Here's how they'll do it.
Your $600 stimulus payout could be worth $1,800 or more if you buy into these high-growth companies.
All three have already made investors a lot of money this year.
Investors should pass on electric-vehicle manufacturer NIO's $61 billion valuation and buy into these superior growth stocks.
Making money comes easy when you own great companies on the leading edge of innovation.